NZ610700A - Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy - Google Patents
Derivatives of heteroarylsulfonamides, their preparation and their application in human therapyInfo
- Publication number
- NZ610700A NZ610700A NZ610700A NZ61070011A NZ610700A NZ 610700 A NZ610700 A NZ 610700A NZ 610700 A NZ610700 A NZ 610700A NZ 61070011 A NZ61070011 A NZ 61070011A NZ 610700 A NZ610700 A NZ 610700A
- Authority
- NZ
- New Zealand
- Prior art keywords
- compounds
- heteroarylsulfonamides
- derivatives
- preparation
- application
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 206010003658 Atrial Fibrillation Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037976 chronic inflammation Diseases 0.000 abstract 1
- 230000006020 chronic inflammation Effects 0.000 abstract 1
- APIZSXNICKBCMT-UHFFFAOYSA-N n-[2-[4-(6-fluoro-1,3-benzoxazol-2-yl)piperazine-1-carbonyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide Chemical compound O1C2=CC(F)=CC=C2N=C1N(CC1)CCN1C(=O)C1=CC=CC=C1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=N1 APIZSXNICKBCMT-UHFFFAOYSA-N 0.000 abstract 1
- VLPMAOQQURVSNS-UHFFFAOYSA-N n-[2-[4-[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]piperazine-1-carbonyl]phenyl]quinoline-8-sulfonamide Chemical compound C1=CN=C2C(S(=O)(=O)NC3=CC=CC=C3C(=O)N3CCN(CC3)C3=NC4=CC=C(C=C4S3)OC(F)(F)F)=CC=CC2=C1 VLPMAOQQURVSNS-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229910052700 potassium Inorganic materials 0.000 abstract 1
- 239000011591 potassium Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1059634A FR2967674B1 (fr) | 2010-11-23 | 2010-11-23 | Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine |
| PCT/EP2011/070736 WO2012069503A1 (en) | 2010-11-23 | 2011-11-23 | Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ610700A true NZ610700A (en) | 2014-12-24 |
Family
ID=44246390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ610700A NZ610700A (en) | 2010-11-23 | 2011-11-23 | Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US8846930B2 (enExample) |
| EP (1) | EP2643318A1 (enExample) |
| JP (1) | JP5837085B2 (enExample) |
| KR (1) | KR101838326B1 (enExample) |
| CN (1) | CN103209980B (enExample) |
| AR (1) | AR083903A1 (enExample) |
| AU (1) | AU2011333772B2 (enExample) |
| BR (1) | BR112013012615A2 (enExample) |
| CA (1) | CA2817531A1 (enExample) |
| FR (1) | FR2967674B1 (enExample) |
| IL (1) | IL226495A (enExample) |
| MA (1) | MA34658B1 (enExample) |
| MX (1) | MX352396B (enExample) |
| MY (1) | MY168283A (enExample) |
| NZ (1) | NZ610700A (enExample) |
| RU (1) | RU2582995C2 (enExample) |
| TW (1) | TWI576106B (enExample) |
| UA (1) | UA109295C2 (enExample) |
| WO (1) | WO2012069503A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20120693A1 (es) | 2009-06-29 | 2012-07-04 | Agios Pharmaceuticals Inc | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) |
| EP2704720B1 (en) * | 2011-05-03 | 2019-08-07 | Agios Pharmaceuticals, Inc. | Pyruvate kinase r activators for use in therapy |
| PT3406251T (pt) | 2011-05-03 | 2024-01-24 | Agios Pharmaceuticals Inc | Ativadores da piruvato-cinase para utilização em terapia |
| WO2014139144A1 (en) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| WO2015055447A1 (en) * | 2013-10-17 | 2015-04-23 | Basf Se | Process for preparing substituted isatoic acid anhydride compounds and derivatives thereof |
| WO2015095111A1 (en) * | 2013-12-18 | 2015-06-25 | Merck Sharp & Dohme Corp. | Diazepane orexin receptor antagonists |
| CN104292179A (zh) * | 2014-10-19 | 2015-01-21 | 湖南华腾制药有限公司 | 一种2-氯苯并[d]恶唑-5-甲醛的制备方法 |
| FR3029112A1 (fr) * | 2014-12-02 | 2016-06-03 | Pf Medicament | Dispersion solide a base de derives d'heteroarylsulfonamides a usage pharmaceutique |
| MX384883B (es) | 2015-06-11 | 2025-03-14 | Agios Pharmaceuticals Inc | Métodos para usar activadores de piruvato cinasa. |
| EP3601273B1 (en) * | 2017-03-24 | 2021-12-01 | Genentech, Inc. | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors |
| CN107556266B (zh) * | 2017-09-12 | 2021-04-23 | 华南农业大学 | 一种2-巯基-4-取代-6-氟苯并噻唑及其制法、应用 |
| US20200131156A1 (en) * | 2018-10-30 | 2020-04-30 | H. Lundbeck A/S | ARYLSULFONYLPYROLECARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS |
| CN113200934B (zh) * | 2021-05-18 | 2022-05-31 | 郑州大学 | 含苯并吗啉酮-联苯骨架化合物及其制备方法和应用 |
| CN113912595B (zh) * | 2021-10-12 | 2024-03-15 | 中国药科大学 | 一类含有噻唑或噻二唑结构的化合物及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5149700A (en) * | 1990-05-30 | 1992-09-22 | American Home Products Corporation | Substituted arylsulfonamides and benzamides |
| DE10128331A1 (de) * | 2001-06-12 | 2002-12-19 | Aventis Pharma Gmbh | Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen |
| PL1828154T3 (pl) * | 2004-12-09 | 2009-10-30 | Hoffmann La Roche | Pochodne fenylopiperazynometanonu |
| EP1902051A1 (en) * | 2005-06-09 | 2008-03-26 | Merck Frosst Canada Ltd. | Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| CN101296914B (zh) * | 2005-08-26 | 2012-07-18 | 盐野义制药株式会社 | 具有ppar激动活性的衍生物 |
| CA2702772A1 (en) * | 2007-10-25 | 2009-04-30 | Boehringer Ingelheim International Gmbh | Diazepane compounds which modulate the cb2 receptor |
| CA2727780A1 (en) * | 2008-06-13 | 2009-12-17 | Bionomics Limited | Novel potassium channel blockers and uses thereof |
| GB0815781D0 (en) * | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
| CN101503392B (zh) * | 2009-03-31 | 2010-12-29 | 中国药科大学 | 芳甲胺类化合物、其制备方法及其医药用途 |
| WO2010130638A1 (en) * | 2009-05-14 | 2010-11-18 | Evotec Ag | Sulfonamide compounds, pharmaceutical compositions and uses thereof |
| PE20120693A1 (es) * | 2009-06-29 | 2012-07-04 | Agios Pharmaceuticals Inc | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) |
-
2010
- 2010-11-23 FR FR1059634A patent/FR2967674B1/fr active Active
-
2011
- 2011-11-03 TW TW100140099A patent/TWI576106B/zh not_active IP Right Cessation
- 2011-11-17 AR ARP110104287A patent/AR083903A1/es unknown
- 2011-11-23 US US13/822,406 patent/US8846930B2/en not_active Expired - Fee Related
- 2011-11-23 NZ NZ610700A patent/NZ610700A/en not_active IP Right Cessation
- 2011-11-23 JP JP2013540331A patent/JP5837085B2/ja not_active Expired - Fee Related
- 2011-11-23 WO PCT/EP2011/070736 patent/WO2012069503A1/en not_active Ceased
- 2011-11-23 AU AU2011333772A patent/AU2011333772B2/en not_active Ceased
- 2011-11-23 CA CA2817531A patent/CA2817531A1/en not_active Abandoned
- 2011-11-23 MY MYPI2013001836A patent/MY168283A/en unknown
- 2011-11-23 MX MX2013005734A patent/MX352396B/es active IP Right Grant
- 2011-11-23 EP EP11785690.6A patent/EP2643318A1/en not_active Withdrawn
- 2011-11-23 KR KR1020137015172A patent/KR101838326B1/ko not_active Expired - Fee Related
- 2011-11-23 BR BR112013012615A patent/BR112013012615A2/pt not_active IP Right Cessation
- 2011-11-23 RU RU2013126251/04A patent/RU2582995C2/ru not_active IP Right Cessation
- 2011-11-23 CN CN201180055123.XA patent/CN103209980B/zh not_active Expired - Fee Related
- 2011-11-23 UA UAA201307746A patent/UA109295C2/uk unknown
-
2013
- 2013-05-13 MA MA35892A patent/MA34658B1/fr unknown
- 2013-05-21 IL IL226495A patent/IL226495A/en active IP Right Grant
-
2014
- 2014-08-15 US US14/460,951 patent/US9156834B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR101838326B1 (ko) | 2018-03-13 |
| HK1187345A1 (en) | 2014-04-04 |
| IL226495A0 (en) | 2013-07-31 |
| BR112013012615A2 (pt) | 2016-09-06 |
| MX2013005734A (es) | 2013-08-01 |
| US8846930B2 (en) | 2014-09-30 |
| AR083903A1 (es) | 2013-04-10 |
| CA2817531A1 (en) | 2012-05-31 |
| FR2967674B1 (fr) | 2012-12-14 |
| UA109295C2 (uk) | 2015-08-10 |
| CN103209980B (zh) | 2015-06-03 |
| CN103209980A (zh) | 2013-07-17 |
| RU2582995C2 (ru) | 2016-04-27 |
| AU2011333772A1 (en) | 2013-06-06 |
| US20140357624A1 (en) | 2014-12-04 |
| RU2013126251A (ru) | 2014-12-27 |
| TW201225951A (en) | 2012-07-01 |
| US20130172326A1 (en) | 2013-07-04 |
| US9156834B2 (en) | 2015-10-13 |
| IL226495A (en) | 2017-06-29 |
| MA34658B1 (fr) | 2013-11-02 |
| AU2011333772B2 (en) | 2016-08-18 |
| EP2643318A1 (en) | 2013-10-02 |
| KR20130119943A (ko) | 2013-11-01 |
| MX352396B (es) | 2017-11-22 |
| FR2967674A1 (fr) | 2012-05-25 |
| JP5837085B2 (ja) | 2015-12-24 |
| WO2012069503A1 (en) | 2012-05-31 |
| JP2014502268A (ja) | 2014-01-30 |
| MY168283A (en) | 2018-10-19 |
| TWI576106B (zh) | 2017-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX377802B (es) | Metodos y composiciones para trastornos del sueño y otros trastornos. | |
| EP4563150A3 (en) | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer | |
| NZ600801A (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
| MX2014000341A (es) | Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades. | |
| SA518392101B1 (ar) | ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ | |
| PH12013501600A1 (en) | Novel heterocyclic derivatives | |
| NZ630099A (en) | Phenicol antibacterials | |
| CL2008002294A1 (es) | Compuestos derivados de benzotiazol acetamida y sus sales farmaceuticamente aceptables; composicion farmaceutica de dichos compuestos; su uso para tratar enfermedades mediadas por pi3 quinasa incluyendo melanoma, carcinoma y otras condiciones derivadas del cancer. | |
| EA201000702A1 (ru) | Некоторые производные 2-пиразинона и их применение в качестве ингибиторов нейтрофильной эластазы | |
| SI2614058T1 (sl) | Polimorfi in soli N-(5-(4-(5-(((2R,6S)-2,6-dimetil-4-morfolinil)metil)-1,3-oksazol-2-il)- 1H-indazol-6-il)-2-(metiloksi)-3-piridinil)metansulfonamida | |
| EA201290255A1 (ru) | Способы и композиции для лечения рака | |
| EA201201658A1 (ru) | Производные пиперидина и их применение для лечения метаболических нарушений | |
| EA201100971A1 (ru) | Производные пиримидининдола для лечения злокачественного новообразования | |
| WO2007101864A3 (en) | Compounds that modulate ppar activity, their preparation and use | |
| EA201500953A1 (ru) | 3-ацетиламино-1-(фенилгетероариламинокарбонил или фенилгетероарилкарбониламино)бензольные производные для лечения гиперпролиферативных нарушений | |
| TN2011000234A1 (en) | Heterocyclically substituted aryl compounds as hif inhibitors | |
| IL232462A (en) | Annals of 2- (1, 2, 3-triazole-2-ram) benzamide and 3- (3,2,1-triazole-2-ram) picolinamide, containing and using pharmaceutical preparations | |
| MX2011006006A (es) | Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos. | |
| GB2511685A (en) | Muscarinic m1 receptor agonists | |
| DK2243772T3 (da) | Hidtil ukendte P2X7R-antagonister og deres anvendelse | |
| MX2014003408A (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][ 1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la beta-secretasa 1 (bace1). | |
| MX2021002255A (es) | Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato. | |
| MX368157B (es) | Formulaciones de sal de meglumina del acido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxilico. | |
| WO2008107092A3 (en) | Use of derivatives of 4-hydroxyphenoxy acetic acid | |
| MX2010007426A (es) | Composiciones farmaceuticas para tratar trastorno del higado graso. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 NOV 2016 BY ACUMASS Effective date: 20151020 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 NOV 2017 BY ACUMASS Effective date: 20161018 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 NOV 2018 BY ACUMASS Effective date: 20171024 |
|
| LAPS | Patent lapsed |